These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice. Davison HR; Taylor S; Drake C; Phuan PW; Derichs N; Yao C; Jones EF; Sutcliffe J; Verkman AS; Kurth MJ Bioconjug Chem; 2011 Dec; 22(12):2593-9. PubMed ID: 22034937 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR. Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980 [TBL] [Abstract][Full Text] [Related]
7. Constrained bithiazoles: small molecule correctors of defective ΔF508-CFTR protein trafficking. Coffman KC; Nguyen HH; Phuan PW; Hudson BM; Yu GJ; Bagdasarian AL; Montgomery D; Lodewyk MW; Yang B; Yoo CL; Verkman AS; Tantillo DJ; Kurth MJ J Med Chem; 2014 Aug; 57(15):6729-38. PubMed ID: 25061695 [TBL] [Abstract][Full Text] [Related]
8. Bithiazole correctors rescue CFTR mutants by two different mechanisms. Loo TW; Bartlett MC; Clarke DM Biochemistry; 2013 Aug; 52(31):5161-3. PubMed ID: 23865422 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein. Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850 [TBL] [Abstract][Full Text] [Related]
10. ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles. Ye L; Hu B; El-Badri F; Hudson BM; Phuan PW; Verkman AS; Tantillo DJ; Kurth MJ Bioorg Med Chem Lett; 2014 Dec; 24(24):5840-5844. PubMed ID: 25452003 [TBL] [Abstract][Full Text] [Related]
11. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. Amico G; Brandas C; Moran O; Baroni D Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989 [TBL] [Abstract][Full Text] [Related]
12. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Wang Y; Bartlett MC; Loo TW; Clarke DM Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886 [TBL] [Abstract][Full Text] [Related]
13. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action. Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis. Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089 [TBL] [Abstract][Full Text] [Related]
15. An overview on chemical structures as ΔF508-CFTR correctors. Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599 [TBL] [Abstract][Full Text] [Related]
16. Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Trinh NT; Bilodeau C; Maillé É; Ruffin M; Quintal MC; Desrosiers MY; Rousseau S; Brochiero E Eur Respir J; 2015 Jun; 45(6):1590-602. PubMed ID: 25792634 [TBL] [Abstract][Full Text] [Related]
17. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR). Caohuy H; Yang Q; Eudy Y; Ha TA; Xu AE; Glover M; Frizzell RA; Jozwik C; Pollard HB J Biol Chem; 2014 Dec; 289(52):35953-68. PubMed ID: 25384981 [TBL] [Abstract][Full Text] [Related]
18. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Verkman AS; Lukacs GL; Galietta LJ Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252 [TBL] [Abstract][Full Text] [Related]
19. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis. Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033 [TBL] [Abstract][Full Text] [Related]
20. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. Bali V; Lazrak A; Guroji P; Fu L; Matalon S; Bebok Z FASEB J; 2016 Jan; 30(1):201-13. PubMed ID: 26336913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]